Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 100 | 2022 | 10525 | 6.910 |
Why?
|
Carcinoma, Neuroendocrine | 19 | 2022 | 319 | 6.170 |
Why?
|
Neuroendocrine Tumors | 24 | 2022 | 534 | 4.340 |
Why?
|
Receptors, Androgen | 31 | 2022 | 1060 | 4.100 |
Why?
|
Gene Expression Regulation, Neoplastic | 34 | 2022 | 8638 | 1.810 |
Why?
|
Androgen Receptor Antagonists | 8 | 2022 | 117 | 1.730 |
Why?
|
Orchiectomy | 8 | 2020 | 456 | 1.520 |
Why?
|
Neoplastic Cells, Circulating | 6 | 2022 | 862 | 1.400 |
Why?
|
Drug Resistance, Neoplasm | 19 | 2021 | 5197 | 1.390 |
Why?
|
Adenocarcinoma | 23 | 2022 | 6338 | 1.380 |
Why?
|
Androgen Antagonists | 17 | 2022 | 1269 | 1.290 |
Why?
|
Carcinoma, Small Cell | 6 | 2019 | 413 | 1.210 |
Why?
|
Prostate | 11 | 2022 | 1564 | 1.110 |
Why?
|
Organoids | 9 | 2022 | 634 | 1.040 |
Why?
|
Phenylthiohydantoin | 8 | 2021 | 192 | 0.860 |
Why?
|
Male | 138 | 2022 | 349524 | 0.830 |
Why?
|
Molecular Targeted Therapy | 9 | 2022 | 2878 | 0.800 |
Why?
|
Neoplasm Metastasis | 18 | 2021 | 5112 | 0.790 |
Why?
|
Disease Progression | 22 | 2022 | 13298 | 0.760 |
Why?
|
Germ-Line Mutation | 5 | 2020 | 1730 | 0.760 |
Why?
|
Cell Line, Tumor | 42 | 2022 | 16959 | 0.730 |
Why?
|
Familial Mediterranean Fever | 1 | 2019 | 66 | 0.710 |
Why?
|
Cell Lineage | 7 | 2021 | 2630 | 0.680 |
Why?
|
Epigenesis, Genetic | 11 | 2021 | 3464 | 0.670 |
Why?
|
Azepines | 3 | 2018 | 338 | 0.670 |
Why?
|
Neuroendocrine Cells | 5 | 2021 | 68 | 0.660 |
Why?
|
Genomics | 11 | 2022 | 5300 | 0.660 |
Why?
|
Humans | 154 | 2022 | 708843 | 0.600 |
Why?
|
Retinoblastoma | 1 | 2019 | 320 | 0.600 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 11 | 2022 | 11253 | 0.600 |
Why?
|
Cisplatin | 4 | 2020 | 1651 | 0.590 |
Why?
|
Molecular Biology | 1 | 2019 | 573 | 0.540 |
Why?
|
Microsatellite Instability | 3 | 2019 | 664 | 0.540 |
Why?
|
Neoplasm Proteins | 5 | 2020 | 3773 | 0.530 |
Why?
|
Nitriles | 9 | 2022 | 950 | 0.530 |
Why?
|
DNA Mismatch Repair | 2 | 2018 | 408 | 0.520 |
Why?
|
Taxoids | 4 | 2020 | 655 | 0.500 |
Why?
|
Genes, myc | 2 | 2016 | 408 | 0.500 |
Why?
|
Gene Dosage | 3 | 2015 | 1271 | 0.500 |
Why?
|
Antineoplastic Agents | 19 | 2022 | 13714 | 0.500 |
Why?
|
Bone Neoplasms | 6 | 2020 | 2579 | 0.490 |
Why?
|
Mutation | 20 | 2022 | 29262 | 0.480 |
Why?
|
Prostatectomy | 7 | 2022 | 1800 | 0.470 |
Why?
|
Benzamides | 8 | 2021 | 1406 | 0.460 |
Why?
|
Prednisone | 2 | 2014 | 1556 | 0.450 |
Why?
|
Gene Expression Profiling | 10 | 2022 | 9556 | 0.440 |
Why?
|
PTEN Phosphohydrolase | 3 | 2020 | 1158 | 0.440 |
Why?
|
Xenograft Model Antitumor Assays | 11 | 2020 | 3714 | 0.430 |
Why?
|
DNA Methylation | 7 | 2022 | 4099 | 0.430 |
Why?
|
Nuclear Proteins | 8 | 2022 | 5982 | 0.420 |
Why?
|
DNA Repair | 6 | 2018 | 2028 | 0.420 |
Why?
|
SOXB1 Transcription Factors | 5 | 2021 | 291 | 0.410 |
Why?
|
DNA Mutational Analysis | 4 | 2019 | 4317 | 0.400 |
Why?
|
Pyrrolidines | 1 | 2012 | 342 | 0.390 |
Why?
|
Tumor Suppressor Protein p53 | 4 | 2020 | 2971 | 0.390 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2022 | 2981 | 0.370 |
Why?
|
Proto-Oncogene Proteins c-myc | 2 | 2017 | 1004 | 0.360 |
Why?
|
Prognosis | 17 | 2021 | 28919 | 0.360 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2013 | 371 | 0.360 |
Why?
|
Medical Oncology | 4 | 2022 | 2098 | 0.360 |
Why?
|
Cell Transdifferentiation | 4 | 2019 | 192 | 0.360 |
Why?
|
DNA Copy Number Variations | 3 | 2022 | 1894 | 0.350 |
Why?
|
Neoplasm Staging | 10 | 2021 | 11126 | 0.340 |
Why?
|
Gene Deletion | 1 | 2016 | 2838 | 0.340 |
Why?
|
High-Throughput Nucleotide Sequencing | 6 | 2021 | 3708 | 0.340 |
Why?
|
Pyrimidines | 3 | 2018 | 2950 | 0.330 |
Why?
|
Antineoplastic Agents, Hormonal | 5 | 2021 | 1521 | 0.320 |
Why?
|
Sequence Analysis, DNA | 4 | 2013 | 4926 | 0.320 |
Why?
|
Hormones | 2 | 2021 | 855 | 0.320 |
Why?
|
Veterans | 1 | 2020 | 2288 | 0.310 |
Why?
|
DNA Helicases | 3 | 2022 | 825 | 0.310 |
Why?
|
Genetic Testing | 2 | 2020 | 3303 | 0.310 |
Why?
|
Retinoblastoma Binding Proteins | 4 | 2020 | 96 | 0.280 |
Why?
|
Immunotherapy | 4 | 2021 | 4057 | 0.280 |
Why?
|
Neoplasms | 11 | 2022 | 20172 | 0.280 |
Why?
|
Prostate-Specific Antigen | 5 | 2020 | 2245 | 0.280 |
Why?
|
Neoplasms, Second Primary | 1 | 2012 | 985 | 0.270 |
Why?
|
Protein Kinase Inhibitors | 7 | 2022 | 5405 | 0.270 |
Why?
|
Genomic Instability | 2 | 2019 | 697 | 0.260 |
Why?
|
Neoplasms, Hormone-Dependent | 2 | 2021 | 414 | 0.260 |
Why?
|
E2F1 Transcription Factor | 2 | 2021 | 195 | 0.250 |
Why?
|
Practice Guidelines as Topic | 4 | 2020 | 7487 | 0.250 |
Why?
|
Liver Neoplasms | 2 | 2017 | 4044 | 0.250 |
Why?
|
Trypsin Inhibitor, Kazal Pancreatic | 2 | 2020 | 22 | 0.240 |
Why?
|
Mice, SCID | 6 | 2019 | 2835 | 0.230 |
Why?
|
Membrane Proteins | 2 | 2022 | 8072 | 0.230 |
Why?
|
Mice, Inbred NOD | 5 | 2019 | 1918 | 0.230 |
Why?
|
Glutamate Carboxypeptidase II | 1 | 2022 | 84 | 0.220 |
Why?
|
Biopsy, Needle | 3 | 2018 | 1682 | 0.210 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2019 | 768 | 0.210 |
Why?
|
Lutetium | 2 | 2019 | 23 | 0.210 |
Why?
|
Mice | 24 | 2022 | 80876 | 0.210 |
Why?
|
Homeodomain Proteins | 4 | 2019 | 2459 | 0.210 |
Why?
|
Animals | 32 | 2022 | 170486 | 0.210 |
Why?
|
Neoplasm Invasiveness | 4 | 2021 | 3693 | 0.210 |
Why?
|
Neoplasms, Complex and Mixed | 2 | 2018 | 32 | 0.210 |
Why?
|
Tumor Cells, Cultured | 3 | 2020 | 6571 | 0.200 |
Why?
|
Transcription, Genetic | 6 | 2021 | 7965 | 0.200 |
Why?
|
Tumor Microenvironment | 3 | 2022 | 2987 | 0.200 |
Why?
|
DNA Repair-Deficiency Disorders | 1 | 2020 | 28 | 0.200 |
Why?
|
Hepatocyte Nuclear Factor 3-alpha | 1 | 2021 | 172 | 0.200 |
Why?
|
Kidney Neoplasms | 3 | 2022 | 3970 | 0.200 |
Why?
|
Proteins | 4 | 2021 | 6151 | 0.200 |
Why?
|
Proto-Oncogene Proteins c-pim-1 | 1 | 2020 | 34 | 0.200 |
Why?
|
Glutamates | 1 | 2022 | 406 | 0.200 |
Why?
|
Signal Transduction | 16 | 2022 | 23950 | 0.200 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2021 | 502 | 0.200 |
Why?
|
Pancreatic Neoplasms | 2 | 2017 | 4930 | 0.200 |
Why?
|
Platinum Compounds | 1 | 2020 | 106 | 0.200 |
Why?
|
Aged, 80 and over | 16 | 2021 | 58184 | 0.190 |
Why?
|
Molecular Probes | 1 | 2022 | 326 | 0.190 |
Why?
|
Anemia, Myelophthisic | 1 | 2019 | 6 | 0.190 |
Why?
|
Urea | 1 | 2022 | 441 | 0.190 |
Why?
|
Benzodiazepinones | 1 | 2019 | 53 | 0.190 |
Why?
|
Radioisotopes | 2 | 2019 | 509 | 0.190 |
Why?
|
Survival Rate | 5 | 2021 | 13202 | 0.180 |
Why?
|
Retinoblastoma Protein | 2 | 2021 | 706 | 0.180 |
Why?
|
Genes, Retinoblastoma | 1 | 2019 | 139 | 0.180 |
Why?
|
Aged | 26 | 2021 | 161488 | 0.180 |
Why?
|
Tristetraprolin | 1 | 2018 | 42 | 0.180 |
Why?
|
Glycoprotein Hormones, alpha Subunit | 1 | 2018 | 97 | 0.180 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2019 | 114 | 0.180 |
Why?
|
Ureteral Neoplasms | 1 | 2019 | 87 | 0.180 |
Why?
|
DNA, Neoplasm | 2 | 2021 | 1782 | 0.180 |
Why?
|
Middle Aged | 26 | 2021 | 213752 | 0.180 |
Why?
|
Organ Culture Techniques | 2 | 2021 | 861 | 0.180 |
Why?
|
Nickel | 1 | 2019 | 127 | 0.180 |
Why?
|
Smad3 Protein | 1 | 2019 | 195 | 0.170 |
Why?
|
Pancytopenia | 1 | 2019 | 106 | 0.170 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2021 | 521 | 0.170 |
Why?
|
Androgens | 3 | 2022 | 1216 | 0.170 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2022 | 356 | 0.170 |
Why?
|
Neuropeptide Y | 1 | 2019 | 200 | 0.170 |
Why?
|
Transcription Factors | 5 | 2021 | 12005 | 0.170 |
Why?
|
Neoadjuvant Therapy | 2 | 2020 | 2561 | 0.170 |
Why?
|
Mass Screening | 2 | 2022 | 5182 | 0.170 |
Why?
|
Colchicine | 1 | 2019 | 251 | 0.170 |
Why?
|
Cohort Studies | 12 | 2021 | 39292 | 0.170 |
Why?
|
Oncogene Proteins | 2 | 2013 | 759 | 0.160 |
Why?
|
Hepatocyte Nuclear Factor 4 | 1 | 2017 | 118 | 0.160 |
Why?
|
Fanconi Anemia Complementation Group A Protein | 1 | 2017 | 49 | 0.160 |
Why?
|
Disease Management | 2 | 2021 | 2536 | 0.160 |
Why?
|
Hepatocyte Nuclear Factor 1-alpha | 1 | 2017 | 153 | 0.160 |
Why?
|
Biopsy | 3 | 2021 | 6766 | 0.160 |
Why?
|
Carcinoma, Renal Cell | 2 | 2022 | 2910 | 0.160 |
Why?
|
Lysine | 1 | 2022 | 1026 | 0.160 |
Why?
|
Drug Therapy | 1 | 2020 | 518 | 0.160 |
Why?
|
Phthalazines | 2 | 2019 | 357 | 0.160 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2021 | 813 | 0.160 |
Why?
|
POU Domain Factors | 1 | 2016 | 38 | 0.160 |
Why?
|
Microtubule-Associated Proteins | 1 | 2022 | 1108 | 0.160 |
Why?
|
Antigens, Surface | 1 | 2022 | 1858 | 0.160 |
Why?
|
Neural Cell Adhesion Molecule L1 | 1 | 2016 | 45 | 0.150 |
Why?
|
Genes, Synthetic | 1 | 2016 | 90 | 0.150 |
Why?
|
Phenotype | 8 | 2022 | 16306 | 0.150 |
Why?
|
Epigenomics | 2 | 2021 | 802 | 0.150 |
Why?
|
Urologic Neoplasms | 1 | 2020 | 316 | 0.150 |
Why?
|
Cytodiagnosis | 2 | 2017 | 416 | 0.150 |
Why?
|
Ubiquitin-Protein Ligases | 4 | 2020 | 1860 | 0.150 |
Why?
|
Drug Screening Assays, Antitumor | 2 | 2017 | 745 | 0.150 |
Why?
|
Genes, Lethal | 1 | 2016 | 255 | 0.150 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 377 | 0.150 |
Why?
|
Pathology, Molecular | 1 | 2019 | 347 | 0.150 |
Why?
|
Early Detection of Cancer | 3 | 2022 | 2865 | 0.150 |
Why?
|
Feedback, Physiological | 1 | 2018 | 480 | 0.140 |
Why?
|
Androstenes | 2 | 2019 | 167 | 0.140 |
Why?
|
DNA-Binding Proteins | 4 | 2022 | 9774 | 0.140 |
Why?
|
Genetic Heterogeneity | 1 | 2019 | 749 | 0.140 |
Why?
|
Genes, Neoplasm | 1 | 2017 | 394 | 0.140 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2020 | 755 | 0.140 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2022 | 8877 | 0.140 |
Why?
|
Treatment Outcome | 9 | 2019 | 61932 | 0.140 |
Why?
|
Serine | 1 | 2019 | 852 | 0.130 |
Why?
|
Leukocyte Count | 1 | 2019 | 1670 | 0.130 |
Why?
|
Ependymoma | 1 | 2017 | 324 | 0.130 |
Why?
|
Cell Differentiation | 6 | 2019 | 11718 | 0.130 |
Why?
|
Down-Regulation | 2 | 2019 | 3093 | 0.130 |
Why?
|
INDEL Mutation | 1 | 2015 | 269 | 0.130 |
Why?
|
Prospective Studies | 8 | 2021 | 50597 | 0.130 |
Why?
|
Terminology as Topic | 3 | 2020 | 1620 | 0.130 |
Why?
|
Feasibility Studies | 2 | 2015 | 4883 | 0.130 |
Why?
|
Culture Techniques | 1 | 2014 | 572 | 0.130 |
Why?
|
Disease Models, Animal | 5 | 2022 | 18375 | 0.130 |
Why?
|
Chromatin | 2 | 2022 | 2693 | 0.130 |
Why?
|
Patient Selection | 4 | 2015 | 4306 | 0.130 |
Why?
|
GPI-Linked Proteins | 1 | 2015 | 453 | 0.130 |
Why?
|
Lung Neoplasms | 5 | 2022 | 12183 | 0.130 |
Why?
|
Autopsy | 1 | 2017 | 990 | 0.130 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2015 | 263 | 0.130 |
Why?
|
Isoenzymes | 1 | 2019 | 1812 | 0.120 |
Why?
|
Cell Survival | 3 | 2020 | 6156 | 0.120 |
Why?
|
Immunohistochemistry | 6 | 2022 | 11790 | 0.120 |
Why?
|
Genes, Tumor Suppressor | 1 | 2018 | 1095 | 0.120 |
Why?
|
Protein Kinase C | 1 | 2019 | 1292 | 0.120 |
Why?
|
Cell Cycle Proteins | 2 | 2022 | 3507 | 0.120 |
Why?
|
Time Factors | 5 | 2020 | 41038 | 0.120 |
Why?
|
Fixatives | 1 | 2012 | 101 | 0.120 |
Why?
|
Gene Regulatory Networks | 1 | 2021 | 1712 | 0.120 |
Why?
|
Purine-Nucleoside Phosphorylase | 1 | 2012 | 24 | 0.110 |
Why?
|
Mutagenesis | 1 | 2016 | 1291 | 0.110 |
Why?
|
Immunoconjugates | 1 | 2019 | 831 | 0.110 |
Why?
|
Enhancer Elements, Genetic | 1 | 2019 | 1378 | 0.110 |
Why?
|
Androstenols | 1 | 2011 | 25 | 0.110 |
Why?
|
Computational Biology | 2 | 2015 | 3568 | 0.110 |
Why?
|
Oncogenes | 1 | 2018 | 1244 | 0.110 |
Why?
|
Genetic Predisposition to Disease | 6 | 2019 | 17218 | 0.110 |
Why?
|
Databases, Genetic | 1 | 2019 | 1807 | 0.110 |
Why?
|
Oncogene Proteins, Fusion | 2 | 2020 | 1597 | 0.110 |
Why?
|
Receptor, erbB-2 | 1 | 2021 | 2307 | 0.110 |
Why?
|
Gene Amplification | 2 | 2014 | 1087 | 0.110 |
Why?
|
Survival Analysis | 3 | 2019 | 10507 | 0.110 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2013 | 626 | 0.110 |
Why?
|
Retrospective Studies | 8 | 2020 | 71483 | 0.110 |
Why?
|
Sarcoma | 1 | 2022 | 1854 | 0.110 |
Why?
|
Tissue Fixation | 1 | 2012 | 258 | 0.110 |
Why?
|
Paraffin Embedding | 1 | 2012 | 317 | 0.110 |
Why?
|
Neuroblastoma | 2 | 2021 | 1180 | 0.100 |
Why?
|
Mice, Knockout | 4 | 2021 | 15274 | 0.100 |
Why?
|
Melanoma | 2 | 2022 | 5194 | 0.100 |
Why?
|
Formaldehyde | 1 | 2012 | 358 | 0.100 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2012 | 371 | 0.100 |
Why?
|
Immunophenotyping | 1 | 2015 | 1908 | 0.100 |
Why?
|
Tumor Suppressor Proteins | 2 | 2019 | 2895 | 0.100 |
Why?
|
Estrogen Receptor alpha | 1 | 2014 | 567 | 0.100 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2012 | 462 | 0.100 |
Why?
|
Genome, Human | 4 | 2021 | 4493 | 0.100 |
Why?
|
Gene Targeting | 1 | 2014 | 915 | 0.100 |
Why?
|
Radioimmunotherapy | 1 | 2010 | 74 | 0.100 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2012 | 547 | 0.100 |
Why?
|
Introns | 1 | 2012 | 1015 | 0.090 |
Why?
|
Venous Thromboembolism | 1 | 2021 | 1537 | 0.090 |
Why?
|
Up-Regulation | 4 | 2020 | 4353 | 0.090 |
Why?
|
Genetic Association Studies | 1 | 2019 | 2709 | 0.090 |
Why?
|
Neoplastic Stem Cells | 3 | 2022 | 1392 | 0.090 |
Why?
|
Piperazines | 2 | 2019 | 2532 | 0.090 |
Why?
|
Cadherins | 1 | 2013 | 921 | 0.090 |
Why?
|
Neoplasm Transplantation | 3 | 2019 | 2165 | 0.090 |
Why?
|
Treatment Failure | 2 | 2011 | 2680 | 0.080 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2020 | 4065 | 0.080 |
Why?
|
Mice, Transgenic | 5 | 2021 | 9927 | 0.080 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2017 | 2029 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 4 | 2020 | 6765 | 0.080 |
Why?
|
Bone Density Conservation Agents | 1 | 2015 | 789 | 0.080 |
Why?
|
Research | 1 | 2016 | 2009 | 0.080 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2015 | 1756 | 0.080 |
Why?
|
Organ Transplantation | 1 | 2017 | 1071 | 0.080 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2021 | 3006 | 0.080 |
Why?
|
Chromosome Deletion | 1 | 2012 | 1380 | 0.080 |
Why?
|
Bone and Bones | 1 | 2017 | 2567 | 0.080 |
Why?
|
Nerve Tissue Proteins | 2 | 2020 | 4592 | 0.080 |
Why?
|
Loss of Heterozygosity | 2 | 2020 | 681 | 0.080 |
Why?
|
Mice, Nude | 3 | 2019 | 3859 | 0.080 |
Why?
|
Stem Cells | 1 | 2020 | 3593 | 0.070 |
Why?
|
Exons | 1 | 2012 | 2472 | 0.070 |
Why?
|
Chromosome Aberrations | 1 | 2013 | 1814 | 0.070 |
Why?
|
Models, Genetic | 1 | 2016 | 3539 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2015 | 2593 | 0.070 |
Why?
|
Follow-Up Studies | 4 | 2021 | 39038 | 0.070 |
Why?
|
Neutrophils | 1 | 2019 | 3867 | 0.070 |
Why?
|
Models, Biological | 2 | 2020 | 9907 | 0.070 |
Why?
|
Cell Proliferation | 5 | 2021 | 10803 | 0.070 |
Why?
|
Drug Discovery | 1 | 2013 | 1066 | 0.070 |
Why?
|
Base Sequence | 1 | 2017 | 13352 | 0.070 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 8896 | 0.070 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 4865 | 0.070 |
Why?
|
Phylogeny | 2 | 2022 | 2799 | 0.070 |
Why?
|
Academic Medical Centers | 1 | 2015 | 2779 | 0.060 |
Why?
|
Trans-Activators | 1 | 2014 | 3053 | 0.060 |
Why?
|
Paneth Cells | 2 | 2014 | 96 | 0.060 |
Why?
|
Sequence Analysis, RNA | 3 | 2019 | 2040 | 0.060 |
Why?
|
Gene Expression | 2 | 2022 | 8014 | 0.060 |
Why?
|
Reproducibility of Results | 3 | 2020 | 19423 | 0.060 |
Why?
|
Risk Assessment | 3 | 2020 | 23284 | 0.060 |
Why?
|
Epithelial-Mesenchymal Transition | 2 | 2021 | 707 | 0.060 |
Why?
|
Insulin | 1 | 2018 | 6648 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2020 | 1400 | 0.060 |
Why?
|
Promoter Regions, Genetic | 3 | 2021 | 6068 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2015 | 11239 | 0.060 |
Why?
|
Receptors, Kainic Acid | 1 | 2022 | 92 | 0.060 |
Why?
|
Predictive Value of Tests | 2 | 2015 | 15252 | 0.050 |
Why?
|
Progesterone Reductase | 1 | 2020 | 14 | 0.050 |
Why?
|
Steroid Isomerases | 1 | 2020 | 19 | 0.050 |
Why?
|
Homeostasis | 1 | 2012 | 3334 | 0.050 |
Why?
|
Ligands | 2 | 2022 | 3297 | 0.050 |
Why?
|
Transcriptional Activation | 2 | 2021 | 1849 | 0.050 |
Why?
|
T-Lymphocytes | 1 | 2019 | 10362 | 0.050 |
Why?
|
Binding Sites | 2 | 2022 | 6276 | 0.050 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2022 | 353 | 0.050 |
Why?
|
Molecular Conformation | 1 | 2022 | 562 | 0.050 |
Why?
|
Hormone Antagonists | 1 | 2020 | 110 | 0.050 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2021 | 443 | 0.050 |
Why?
|
Transcription Factor AP-1 | 1 | 2022 | 332 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2017 | 8024 | 0.050 |
Why?
|
Cell Nucleus | 2 | 2021 | 3021 | 0.050 |
Why?
|
Quality of Life | 1 | 2021 | 11594 | 0.050 |
Why?
|
Indolizines | 1 | 2019 | 34 | 0.050 |
Why?
|
Casein Kinase I | 1 | 2020 | 46 | 0.050 |
Why?
|
Enzyme Inhibitors | 1 | 2011 | 3936 | 0.050 |
Why?
|
Cyclic N-Oxides | 1 | 2019 | 78 | 0.050 |
Why?
|
Repressor Proteins | 2 | 2022 | 3075 | 0.050 |
Why?
|
Pyridinium Compounds | 1 | 2019 | 80 | 0.050 |
Why?
|
RNA-Binding Proteins | 2 | 2022 | 1920 | 0.050 |
Why?
|
Mice, Inbred C57BL | 4 | 2021 | 22989 | 0.050 |
Why?
|
Phosphoramide Mustards | 1 | 2019 | 16 | 0.050 |
Why?
|
Co-Repressor Proteins | 1 | 2020 | 183 | 0.050 |
Why?
|
Case-Control Studies | 4 | 2019 | 21194 | 0.050 |
Why?
|
Platinum | 1 | 2020 | 220 | 0.050 |
Why?
|
Receptors, Dopamine D2 | 1 | 2021 | 473 | 0.050 |
Why?
|
Disease-Free Survival | 2 | 2022 | 7026 | 0.050 |
Why?
|
Ultracentrifugation | 1 | 2019 | 199 | 0.050 |
Why?
|
Carbazoles | 1 | 2021 | 249 | 0.050 |
Why?
|
Cyclin-Dependent Kinase 5 | 1 | 2019 | 112 | 0.050 |
Why?
|
Octamer Transcription Factor-3 | 1 | 2020 | 243 | 0.050 |
Why?
|
Activating Transcription Factor 4 | 1 | 2019 | 80 | 0.040 |
Why?
|
Alternative Splicing | 2 | 2016 | 1123 | 0.040 |
Why?
|
Evidence-Based Medicine | 1 | 2011 | 3690 | 0.040 |
Why?
|
Muscular Atrophy | 1 | 2022 | 352 | 0.040 |
Why?
|
Integrins | 1 | 2022 | 830 | 0.040 |
Why?
|
Nitroimidazoles | 1 | 2019 | 114 | 0.040 |
Why?
|
Biosynthetic Pathways | 1 | 2019 | 141 | 0.040 |
Why?
|
Tissue Culture Techniques | 1 | 2019 | 295 | 0.040 |
Why?
|
RNA Interference | 2 | 2021 | 3026 | 0.040 |
Why?
|
Interferon-alpha | 1 | 2022 | 892 | 0.040 |
Why?
|
Spliceosomes | 1 | 2018 | 110 | 0.040 |
Why?
|
Germ Cells | 1 | 2022 | 588 | 0.040 |
Why?
|
S-Adenosylmethionine | 1 | 2019 | 206 | 0.040 |
Why?
|
Protein Binding | 2 | 2022 | 9639 | 0.040 |
Why?
|
Receptors, Glucocorticoid | 1 | 2019 | 308 | 0.040 |
Why?
|
Nucleotides | 1 | 2020 | 440 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2017 | 6497 | 0.040 |
Why?
|
Female | 8 | 2022 | 375205 | 0.040 |
Why?
|
Fluorescent Antibody Technique | 1 | 2022 | 2673 | 0.040 |
Why?
|
Cullin Proteins | 1 | 2018 | 185 | 0.040 |
Why?
|
Urothelium | 1 | 2019 | 285 | 0.040 |
Why?
|
Etoposide | 1 | 2018 | 631 | 0.040 |
Why?
|
BRCA2 Protein | 1 | 2022 | 690 | 0.040 |
Why?
|
Protein Isoforms | 1 | 2021 | 1712 | 0.040 |
Why?
|
Protein Subunits | 1 | 2020 | 1021 | 0.040 |
Why?
|
MicroRNAs | 1 | 2012 | 3655 | 0.040 |
Why?
|
Pilot Projects | 2 | 2022 | 7994 | 0.040 |
Why?
|
Hydrogels | 1 | 2021 | 648 | 0.040 |
Why?
|
Multienzyme Complexes | 1 | 2020 | 769 | 0.040 |
Why?
|
Cell Hypoxia | 1 | 2019 | 686 | 0.040 |
Why?
|
Polymerase Chain Reaction | 2 | 2019 | 6293 | 0.040 |
Why?
|
Structure-Activity Relationship | 1 | 2022 | 3209 | 0.040 |
Why?
|
Cell Cycle | 2 | 2015 | 3014 | 0.040 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 1146 | 0.030 |
Why?
|
Carboplatin | 1 | 2018 | 797 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2014 | 12447 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2020 | 1728 | 0.030 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2019 | 611 | 0.030 |
Why?
|
Biological Evolution | 1 | 2020 | 1084 | 0.030 |
Why?
|
Pharmacology | 1 | 2014 | 112 | 0.030 |
Why?
|
Fanconi Anemia | 1 | 2017 | 326 | 0.030 |
Why?
|
Adult | 8 | 2021 | 211041 | 0.030 |
Why?
|
Molecular Imaging | 1 | 2022 | 853 | 0.030 |
Why?
|
Carcinoma, Acinar Cell | 1 | 2014 | 59 | 0.030 |
Why?
|
DNA | 2 | 2019 | 7172 | 0.030 |
Why?
|
Breast | 1 | 2022 | 1782 | 0.030 |
Why?
|
Carcinoma, Large Cell | 1 | 2014 | 111 | 0.030 |
Why?
|
Fluorescent Dyes | 1 | 2022 | 1977 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2019 | 12292 | 0.030 |
Why?
|
Extracellular Matrix | 1 | 2021 | 1794 | 0.030 |
Why?
|
Chromosome Breakpoints | 1 | 2013 | 98 | 0.030 |
Why?
|
Gene Knockout Techniques | 1 | 2016 | 819 | 0.030 |
Why?
|
Death | 1 | 2017 | 573 | 0.030 |
Why?
|
Paclitaxel | 1 | 2020 | 1655 | 0.030 |
Why?
|
Consensus | 1 | 2022 | 2713 | 0.030 |
Why?
|
Clone Cells | 1 | 2016 | 1767 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2017 | 605 | 0.030 |
Why?
|
Thionucleosides | 1 | 2012 | 14 | 0.030 |
Why?
|
Piperidines | 1 | 2021 | 1582 | 0.030 |
Why?
|
Deoxyadenosines | 1 | 2012 | 26 | 0.030 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2017 | 507 | 0.030 |
Why?
|
Carcinoid Tumor | 1 | 2014 | 241 | 0.030 |
Why?
|
Thioguanine | 1 | 2012 | 56 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2010 | 9584 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2022 | 3179 | 0.030 |
Why?
|
Urethral Neoplasms | 1 | 2012 | 40 | 0.030 |
Why?
|
British Columbia | 1 | 2012 | 228 | 0.030 |
Why?
|
Internationality | 1 | 2018 | 1002 | 0.030 |
Why?
|
History, 20th Century | 1 | 2020 | 2837 | 0.030 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2014 | 916 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2020 | 3515 | 0.030 |
Why?
|
Triazoles | 1 | 2017 | 910 | 0.030 |
Why?
|
Histones | 1 | 2021 | 2579 | 0.030 |
Why?
|
Models, Molecular | 1 | 2022 | 5525 | 0.030 |
Why?
|
Benzodiazepines | 1 | 2017 | 1067 | 0.030 |
Why?
|
Hospice Care | 1 | 2017 | 609 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2019 | 14836 | 0.030 |
Why?
|
Tubulin | 1 | 2014 | 755 | 0.030 |
Why?
|
Nomograms | 1 | 2012 | 225 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2020 | 4310 | 0.020 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2015 | 1126 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2015 | 1829 | 0.020 |
Why?
|
Gene Fusion | 1 | 2012 | 377 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2019 | 3645 | 0.020 |
Why?
|
Risk | 1 | 2021 | 9641 | 0.020 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2018 | 2118 | 0.020 |
Why?
|
CpG Islands | 1 | 2013 | 1177 | 0.020 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2012 | 726 | 0.020 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2010 | 330 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2018 | 2936 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2019 | 6127 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2014 | 2668 | 0.020 |
Why?
|
Esophageal Neoplasms | 1 | 2017 | 1449 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 3 | 2021 | 34151 | 0.020 |
Why?
|
Genotype | 1 | 2022 | 12863 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2021 | 4254 | 0.020 |
Why?
|
Cell Division | 1 | 2015 | 4752 | 0.020 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2010 | 632 | 0.020 |
Why?
|
Blotting, Western | 1 | 2015 | 5456 | 0.020 |
Why?
|
Cause of Death | 1 | 2017 | 3497 | 0.020 |
Why?
|
Proteomics | 1 | 2019 | 3244 | 0.020 |
Why?
|
Gene Frequency | 1 | 2013 | 3701 | 0.020 |
Why?
|
Tissue and Organ Procurement | 1 | 2013 | 850 | 0.020 |
Why?
|
Colonic Neoplasms | 1 | 2017 | 2535 | 0.020 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2017 | 1962 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2012 | 2750 | 0.020 |
Why?
|
Research Design | 1 | 2020 | 5833 | 0.020 |
Why?
|
Cancer Vaccines | 1 | 2011 | 1017 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2012 | 2951 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2020 | 9488 | 0.020 |
Why?
|
Transfection | 1 | 2012 | 6161 | 0.020 |
Why?
|
Blood Glucose | 1 | 2018 | 6255 | 0.020 |
Why?
|
Head and Neck Neoplasms | 1 | 2017 | 2591 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2015 | 5235 | 0.010 |
Why?
|
Databases, Factual | 1 | 2018 | 7763 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2013 | 15485 | 0.010 |
Why?
|
Cell Movement | 1 | 2015 | 5489 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 7089 | 0.010 |
Why?
|
Decision Support Techniques | 1 | 2012 | 2029 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2017 | 6170 | 0.010 |
Why?
|
Ovarian Neoplasms | 1 | 2017 | 4712 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2010 | 2708 | 0.010 |
Why?
|
Age Factors | 1 | 2016 | 18712 | 0.010 |
Why?
|
Genetic Variation | 1 | 2014 | 6666 | 0.010 |
Why?
|
Incidence | 1 | 2016 | 20320 | 0.010 |
Why?
|
Child, Preschool | 1 | 2017 | 41081 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2013 | 11738 | 0.010 |
Why?
|
Algorithms | 1 | 2014 | 13647 | 0.010 |
Why?
|
Risk Factors | 1 | 2020 | 69553 | 0.010 |
Why?
|
United States | 1 | 2020 | 67165 | 0.010 |
Why?
|